PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and safety. RESULTS: The primary end point was the rate of complete remission with undetectable minimal residual disease by flow cytometry in both the blood and bone marrow 2 months after completion of treatment, which was 28% in both groups. The overall response rate at that time was 84% in treatment-naïve patients and 88% in relapsed or refractory patients. At that time, 67% of treatment-naïve patients and 50% of relapsed or refractory patients had undetectable minimal residual disease in both the blood and marrow. At a median follow-up of 24.2 months in treatment-naïve patients and 21.5 months in relapsed or refractory patients, the median progression-free and overall survival times were not yet reached, with only 1 patient experiencing progression and 1 death. Neutropenia and thrombocytopenia were the most frequent adverse events, followed by hypertension. Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in the relapsed or refractory cohort. There was only 1 episode of neutropenic fever. A favorable impact on both perceived and objective cognitive performance during treatment was observed. CONCLUSION: The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.
PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and safety. RESULTS: The primary end point was the rate of complete remission with undetectable minimal residual disease by flow cytometry in both the blood and bone marrow 2 months after completion of treatment, which was 28% in both groups. The overall response rate at that time was 84% in treatment-naïve patients and 88% in relapsed or refractory patients. At that time, 67% of treatment-naïve patients and 50% of relapsed or refractory patients had undetectable minimal residual disease in both the blood and marrow. At a median follow-up of 24.2 months in treatment-naïve patients and 21.5 months in relapsed or refractory patients, the median progression-free and overall survival times were not yet reached, with only 1 patient experiencing progression and 1 death. Neutropenia and thrombocytopenia were the most frequent adverse events, followed by hypertension. Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in the relapsed or refractory cohort. There was only 1 episode of neutropenic fever. A favorable impact on both perceived and objective cognitive performance during treatment was observed. CONCLUSION: The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.
Authors: Anthony R Mato; Lindsey E Roeker; Toby A Eyre; Chadi Nabhan; Nicole Lamanna; Brian T Hill; Danielle M Brander; Paul M Barr; Frederick Lansigan; Bruce D Cheson; Arun K Singavi; Maryam Sarraf Yazdy; Nirav N Shah; John N Allan; Erica B Bhavsar; Joanna Rhodes; Kaitlin Kennard; Stephen J Schuster; AnnaLynn M Williams; Alan P Skarbnik; Andre H Goy; Julie M Goodfriend; Colleen Dorsey; Catherine C Coombs; Hande Tuncer; Chaitra S Ujjani; Ryan Jacobs; Allison M Winter; John M Pagel; Neil Bailey; Anna Schuh; Mazyar Shadman; Andrea Sitlinger; Hanna Weissbrot; Sivraj Muralikrishnan; Andrew Zelenetz; Amy A Kirkwood; Christopher P Fox Journal: Blood Adv Date: 2019-05-28
Authors: Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek Journal: N Engl J Med Date: 2019-06-04 Impact factor: 91.245
Authors: Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn Journal: Lancet Oncol Date: 2018-12-03 Impact factor: 41.316
Authors: John F Seymour; Thomas J Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; John Gerecitano; Tadeusz Robak; Javier De la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Rod Humerickhouse; Elizabeth A Punnoose; Yan Li; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Arnon P Kater Journal: N Engl J Med Date: 2018-03-22 Impact factor: 91.245
Authors: Pascal Jean-Pierre; Paul C Winters; Tim A Ahles; Michael Antoni; F Daniel Armstrong; Frank Penedo; Steven E Lipshultz; Tracie L Miller; Kevin Fiscella Journal: J Oncol Pract Date: 2011-11-22 Impact factor: 3.840
Authors: Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater Journal: Blood Adv Date: 2019-09-10
Authors: Jacqueline C Barrientos; Susan O'Brien; Jennifer R Brown; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine Tam; Stephen Mulligan; Ulrich Jaeger; Stephen Devereux; Christopher Pocock; Tadeusz Robak; Stephen J Schuster; Anna Schuh; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Gavin Cull; Mike Hamblin; Jeffrey A Jones; Karl Eckert; Isabelle G Solman; Samuel Suzuki; Emily Hsu; Danelle F James; John C Byrd; Peter Hillmen Journal: Clin Lymphoma Myeloma Leuk Date: 2018-08-18
Authors: William G Wierda; John N Allan; Tanya Siddiqi; Thomas J Kipps; Stephen Opat; Alessandra Tedeschi; Xavier C Badoux; Bryone J Kuss; Sharon Jackson; Carol Moreno; Ryan Jacobs; John M Pagel; Ian Flinn; Yvonne Pak; Cathy Zhou; Edith Szafer-Glusman; Joi Ninomoto; James P Dean; Danelle F James; Paolo Ghia; Constantine S Tam Journal: J Clin Oncol Date: 2021-10-07 Impact factor: 44.544
Authors: Inhye E Ahn; Carsten U Niemann; Christian Brieghel; Kathrine Aarup; Mathias H Torp; Michael A Andersen; Christina W Yde; Xin Tian; Adrian Wiestner Journal: Clin Cancer Res Date: 2021-05-07 Impact factor: 13.801
Authors: Sanjal Desai; Clifton Mo; Erika M Gaglione; Constance M Yuan; Maryalice Stetler-Stevenson; Xin Tian; Irina Maric; Laura Wake; Mohammed Z Farooqui; Dennis C Drinkwater; Susan Soto; Janet Valdez; Thomas E Hughes; Pia Nierman; Jennifer Lotter; Gerald E Marti; Christopher Pleyer; Clare Sun; Jeanine Superata; Cydney Nichols; Sarah E M Herman; Margaret A Lindorfer; Ronald P Taylor; Adrian Wiestner; Inhye E Ahn Journal: Leuk Lymphoma Date: 2021-03-02
Authors: Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati Journal: Int J Mol Sci Date: 2021-06-22 Impact factor: 5.923
Authors: Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner Journal: Blood Date: 2021-11-11 Impact factor: 22.113